

Abstract of the Disclosure

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy of the formula

5

A-D-B wherein

D is -NH-C(O)-NH-

A is a substituted moiety of the formula: $-L-(M-L^1)_q$,

and

B is a substituted or unsubstituted up to tricyclic aryl or heteroaryl moiety with a t

10

least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen oxygen and sulfur.

L is a 5-6 membered cyclic structure bound directly to D,

L^1 comprises a substituted cyclic moiety having at least 5 members

M is a bridging group having at least one atom and q is an integer of from 1-3.